REVIEW PAPER
Do we still need renal biopsy in lupus nephritis?
Submission date: 2016-03-17
Acceptance date: 2016-05-03
Online publication date: 2016-06-03
Publication date: 2016-04-30
Reumatologia 2016;54(2):61-66
KEYWORDS
TOPICS
ABSTRACT
The natural course of systemic lupus erythematosus (SLE) is characterized by periods of disease activity and remissions. Prolonged disease activity results in cumulative organ damage. Lupus nephritis is one of the most common and devastating manifestations of SLE. In the era of changing therapy to less toxic regimens, some authors have stated that if mycophenolate mofetil can be used for the induction and maintenance treatment in all histological classes of lupus nephritis, renal biopsy can be omitted. This article aims to answer the question of what brings the bigger risk: renal biopsy or its abandonment.
REFERENCES (47)
1.
Sutton EJ, Davidson JE, Bruce IN. The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review. Semin Arthritis Rheum 2013; 43: 352-361.
2.
Lopez R, Davidson JE, Beeby MD, et al. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology (Oxford) 2012; 51: 491-498.
3.
Danila MI, Pons-Estel GJ, Zhang J, et al. Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic cohort. Rheumatology (Oxford) 2009; 48: 542-545.
4.
Davidson A, Aranow C. Lupus nephritis: lessons from murine models. Nat Rev Rheumatol 2010; 6: 13-20.
5.
Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677-2686.
6.
Bertsias GK, Tektonidou M, Amoura Z, et al.; European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771-1782.
7.
Hahn BH, McMahon MA, Wilkinson A, et al.; American College of Rheumatology. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64: 797-808.
8.
Ruiz Irastorza G, Espinosa G, Frutos MA, et al.; Spanish Society of Internal Medicine (SEMI); Spanish Society of Nephrology (SEN). Diagnosis and treatment of lupus nephritis. Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and Spanish Society of Nephrology (SEN). Nefrologia 2012; 32 Suppl 1: 1-35.
9.
Van Tellingen A, Voskuyl AE, Vervloet MG, et al.; Dutch Working Party on Systemic Lupus Erythematosus. Dutch guidelines for diagnosis and therapy of proliferative lupus nephritis. Neth J Med 2012; 70: 199-207.
10.
Markowitz GS, D’Agati VD. The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years. Kidney Int 2007; 71: 491-495.
11.
Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-250.
12.
Christopher-Stine L, Siedner MJ, Lin J, et al. Renal biopsy in lupus patients with low levels of proteinuria. J Rheumatol 2007; 34: 332-335.
13.
De Rosa M, Toblli J, De Rosa G, et al. Could proteinuria less than 500 mg/d be an actual indicator of lupus nephritis biopsy? J Am Soc Nephrol 2013 [Annual Meeting Abstracts: PO720].
14.
Hebert LA, Sharma HM, Sedmak DD, et al. Unexpected renal biopsy findings in a febrile systemic lupus erythematosus patient with worsening renal function and heavy proteinuria. Am J Kidney Dis 1989; 13: 504-507.
15.
Baranowska-Daca E, Choi YJ, Barrios R, et al. Non-lupus nephritides in patients with systemic lupus erythematosus: a comprehensive clinicopathologic study and review of the literature. Hum Pathol 2001; 32: 1125-1135.
16.
Kraft SW, Schwartz MM, Korbet SM, et al. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol 2005; 16: 175-179.
17.
Mok CC, Cheung TT, Lo WH. Minimal mesangial lupus nephritis: a systematic review. Scand J Rheumatol 2010; 39: 181-189.
18.
Shea-Simonds P, Cairns TD, Roufosse C, et al. Lupus podocytopathy. Rheumatology (Oxford) 2009; 48: 1616-1618.
19.
Wang GB, Xu ZJ, Liu HF, et al. Changes in pathological pattern and treatment regimens based on repeat renal biopsy in lupus nephritis. Chin Med J (Engl) 2012; 125: 2890-2894.
20.
Lee HS, Mujais SK, Kasinath BS, et al. Course of renal pathology in patients with systemic lupus erythematosus. Am J Med 1984; 77: 612-620.
21.
Parikh S, Hebert L, Rovin B. Protecting the kidneys in lupus nephritis. Int J Clin Rheumatol 2011; 6: 529-546.
22.
Daugas E, Nochy D, Huong DL, et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol 2002; 13: 42-52.
23.
Tektonidou MG. Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy. Clin Rev Allergy Immunol 2009; 36: 131-140.
24.
Tektonidou MG, Sotsiou F, Moutsopoulos HM. Antiphospholipid syndrome nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS. J Rheumatol 2008; 35: 1983-1988.
25.
Parikh SV, Rovin BH. Antiphospholipid syndrome nephropathy: an insidious cause of progressive renal failure. In: Vasoocclusive disorders and kidney disease, Nachman PH, Clark WF, Derebail VK (eds.). Washington, DC: American Society of Nephrology; 2014; 13: 1-6.
26.
Hill GS, Delahousse M, Nochy D, et al. Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int 2001; 59: 304-316.
27.
Askenazi D, Myones B, Kamdar A, et al. Outcomes of children with proliferative lupus nephritis: the role of protocol renal biopsy. Pediatr Nephrol 2007; 22: 981-986.
28.
Hill GS, Delahouse M, Nochy D, et al. A new morphologic index for the evaluation of renal biopsies in lupus nephritis. Kidney Int 2000; 58: 1160-1173.
29.
Alsuwaida A, Husain S, Alghonaim M, et al. Strategy for second kidney biopsy in patients with lupus nephritis. Nephrol Dial Transplant 2012; 27: 1472-1478.
30.
Esdaile JM, Joseph L, Mackenzie T, et al. The pathogenesis and prognosis of lupus nephritis: information from repeat renal biopsy. Semin Arthritis Rheum 1993; 23: 135-148.
31.
Gunnarsson I, Sundelin B, Heimburger M, et al. Repeated renal biopsy in proliferative lupus nephritis – predictive role of serum C1q and albuminuria. J Rheumatol 2002; 29: 693-699.
32.
Austin HA 3rd, Muenz LR, Joyce KM, et al. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 1983; 75: 382-391.
33.
Austin HA 3rd, Muenz LR, Joyce KM, et al. Diffuse proliferative lupus nephritis: Identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25: 689-695.
34.
Moroni G, Pasquali S, Quaglini S, et al. Clinical and prognostic value of serial renal biopsies in lupus nephritis. Am J Kidney Dis 1999; 34: 530-539.
35.
McRae M, Rousseau-Gagnon M, Philibert D, et al. The interpretation of repeat renal biopsies in patients with lupus nephritis. Rheumatology (Oxford) 2014; 53: 1151-1152.
36.
Chen YE, Korbet SM, Katz RS, et al. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 2008; 3: 46-53.
37.
Grootscholten C, Bajema IM, Florquin S, et al. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum 2007; 56: 924-937.
38.
Pillemer SR, Austin HA 3rd, Tsokos GC, Balow JE. Lupus nephritis: Association between serology and renal biopsy measures. J Rheumatol 1988; 15: 284-288.
39.
Alvarado AS, Malvar A, Lococo B, et al. The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients. Lupus 2014; 23: 840-847.
40.
Ong LM, Hooi LS, Lim TO, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 2005; 10: 504-510.
41.
Hu W, Liu Z, Chen H, et al. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chinese Med J 2002; 115: 705-709.
42.
Alsuwaida A. The clinical significance of serial kidney biopsies in lupus nephritis. Mod Rheumatol 2014; 24: 453-456.
43.
Norby GE, Strøm EH, Midtvedt K, et al. Recurrent lupus nephritis after kidney transplantation: a surveillance biopsy study. Ann Rheum Dis 2010; 69: 1484-1487.
44.
Daleboudt GM, Bajema IM, Goemaere NN, et al. The clinical relevance of a repeat biopsy in lupus nephritis flares. Nephrol Dial Transplant 2009; 24: gfp359.
45.
Parikh SV, Alvarado A, Malvar A, Rovin BH. The Kidney Biopsy in Lupus Nephritis: Past, Present, and Future. Semin Nephrol 2015; 35: 465-477.
46.
Rabbani MA, Habib HB, Islam B, et al. Early renal damage assessed by the SLICC/ACR damage index is predictor of severe outcome in lupus patients in Pakistan. Lupus 2010; 19: 1573-1578.
47.
Yap DY, Tang CS, Ma MK, et al. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant 2012; 27: 3248-3254.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
